A nthocyanins, as a group of flavonoids, are most abundant in various colorful fruits, vegetables, red wine, and grains. 1 Epidemiological and animal investigations have shown that anthocyanins reduce the severity or risk of atherosclerosis. [2] [3] [4] [5] Many in vitro studies have revealed that anthocyanins have antioxidant and anti-inflammatory properties as well as capability in promoting cholesterol efflux from macrophages. 1, 6, 7 However, the effective levels were determined at a range between 10 to 200 μmol/L. In vivo intervention in human subjects and most animal test systems have shown that only approximately 0.1% of the intact anthocyanins are typically absorbed, and the maximum plasma concentration (Cmax) of anthocyanins is usually less than 0.1 μmol/L. [8] [9] [10] Recent studies have suggested that after the ingestion, anthocyanins are rapidly biotransformed into various metabolites, 11, 12 raising the possibility that those metabolites, either working on their own or in combination with the parent anthocyanins, in protecting the subjects from developing atherosclerosis. September 28, 2012 metabolism of Cy-3-G or produced by the spontaneous degradation of Cy-3-G under physiological conditions at neutral pH. [15] [16] [17] Moreover, if PCA is among the primary contributors in attenuating atherosclerotic lesions, mechanisms underlying the function of PCA remain to be explored.
Plasma high-density lipoprotein cholesterol (HDL-C) levels inversely correlate with the development of atherosclerotic diseases. 18 In addition to its antioxidative and anti-inflammatory properties, HDL may attenuate atherosclerosis via stimulating reverse cholesterol transport (RCT), a process that entails the efflux of excess cholesterol from macrophages into the liver followed by its excretion into the bile and then the feces. 19 The promotion of macrophage RCT is a potential novel approach for atherosclerosis prevention and treatment, which can be achieved by upregulating the expression of ATP-binding cassette transporter A1 (ABCA1) and G1 (ABCG1) in macrophages. 20 MicroRNA (miRNA) regulates gene expression through recognizing the 3′-untranslated region (3′-UTR) of its target mRNA to repress its translation or facilitate its cleavage. 21 Recently, a few miRNAs, including miRNA-33 (miR-33) 22 and miR-758, 23 were shown to inhibit macrophage cholesterol efflux by downregulating ABCA1 or ABCG1 expression. Whether there are other miRNAs in macrophages that modulate ABCA1 and ABCG1 expression remain unknown. In the present study, we investigated the contribution of PCA in the antiatherosclerotic effects of the parent Cy-3-G, determined its effect in promoting macrophage RCT, and revealed the existence of a novel mechanism by which PCA represses miR-10b expression, increases ABCA1 and ABCG1 expression, and accelerates macrophage RCT in the ApoE −/− mice.
Methods

Gut Microbiota Metabolism of Cy-3-G
The metabolism of Cy-3-G (Polyphenols AS, Sandnes, Norway) was investigated in both ApoE −/− mice (Jackson Laboratories, Sacramento, CA) and germ-free Kunming mice (Third Military Medical University, Chongqing, China). All of the animal procedures were approved by the Animal Care and User Committee of Sun Yat-Sen University. The expanded Methods are available in the Online Data Supplement.
Cell Culture
Mouse peritoneal macrophages (MPMs) from adult C57BL/6J mice (Jackson Laboratories) were obtained by peritoneal lavage 4 days after the intraperitoneal injection of a 1.0-mL volume of 4% thioglycollate. 13 The thioglycollate-elicited MPMs were maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS) (Gibco BRL, Grand Island, NY). Unless otherwise stated, references to MPMs concern the thioglycollate-elicited MPMs. J774.A1 (J774) murine macrophages, human THP-1 monocytes, and HEK293 cells were obtained from the American Type Culture Collection (Manassas, VA) and cultured per manufacturer's instructions. The differentiation of THP-1 monocytes into macrophages was induced in the presence of 167 nmol/L phorbol 12-myristate 13-acetate (Wako, Tokyo, Japan) for 48 hours. 24 
In Vitro Cholesterol Efflux Assays
Assays of cellular cholesterol efflux were performed as described previously. 7 Details are provided in the Online Data Supplement.
Quantitative Real-Time RT-PCR
Total RNA from cells was isolated using the miRNeasy isolation kit (Qiagen, Hilden, Germany). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) on the Applied Biosystems 7000 sequence detection system. GAPDH mRNA was used as the internal control. Primer sequences for all the genes examined in this study are shown in Online Table I . For miRNA quantification, total RNA was reverse-transcribed using the RT 2 miRNA First Strand kit (SABiosciences, San Diego, CA). Primers specific for mouse miR-10b, miR-300, miR-370, and miR-493 (SABiosciences) were used and the values were normalized to U6 as a housekeeping gene.
ABCA1 and ABCG1 mRNA Stability Assay
Actinomycin D (ActD) (Sigma-Aldrich, St Louis, MO), a transcriptional inhibitor, 25 was used to examine the effect of Cy-3-G or PCA (Sigma-Aldrich) on ABCA1 and ABCG1 mRNA stability. The expanded Methods are available in the Online Data Supplement.
miRNA Microarray Analysis
MPMs preloaded with acetylated low-density lipoprotein (AcLDL) (25 μg/mL) for 24 hours were incubated in RPMI 1640 medium containing 0.1% bovine serum albumin and PCA (1 μmol/L) or the vehicle (DMSO) for another 24 hours. Total RNA was extracted 
3′-UTR 3′-untranslated region
using Trizol and the miRNeasy Mini Kit (Qiagen). The RNA quality and quantity were determined with a Nanodrop spectrophotometer (ND-1000, Nanodrop Technologies), and the RNA integrity was determined by gel electrophoresis. The labeling, hybridization, and scanning of the isolated RNA were performed by Exiqon (Denmark) using an LNA miRCURY array (v.16.0). The scanned images were then imported into the GenePix Pro 6.0 software (Axon) for grid alignment and data extraction. The miRNA expression levels that were modulated with Fold Change Filtering (treated/control) of 2.0 or more were considered to be differentially expressed.
miR-10b and Anti-miR-10b Transfection
MPMs and THP-1 macrophages preloaded with or without AcLDL and HEK293 were transfected with miRIDIAN miRNA mimics (miR-10b) or with miRIDIAN miRNA inhibitors (antienmiR-10b) (Dharmacon, Lafayette, CO) at the concentrations indicated in the corresponding figure legends, using Oligofectamine (Invitrogen) for 48 hours. All the control samples were treated with an equal concentration of a nontargeting negative control mimic sequence (Con miR) or an inhibitor negative control sequence (Con Inh) (Dharmacon) for use as controls for nonensequence-specific effects in the miRNA experiments.
3′-UTR Vector Construction and Luciferase Reporter Assays
The entire 3′-UTRs sequences of mouse ABCA1 (mABCA1) (3153 nt, NM_013454), mABCG1 (3696 nt, NM_009593), hABCA1 (3309 nt, NM_005502), and hABCG1 (850 nt, NM_004915) were cloned into the EcoRV and Xba1 sites of pGL3 cm created based on the vector pGL3-control (Promega), generating the pGL3-m/hAB-CA1-WT and pGL3-m/hABCG1-WT constructs. Point mutations in the seed regions of predicted miR-10b sites within the 3′-UTRs of m/h ABCA1 and ABCG1 were generated using QuikChange Multi Site-Directed Mutagenesis (Stratagene) according to the manufacturer's protocol. All the constructs were confirmed by sequencing. For the luciferase reporter assay, HEK293 cells were seeded at 1×10 4 cells/well in a 96-well plate 24 hours before transfection. The cells were cotransfected with a series of concentrations of miR-10b mimics or negative control mimics (Dharmacon) (60 nmol/L), either 50 ng of pGL3-WT or pGL3-mutation and 50 ng of pRL-TK (Promega) by Lipofectamine 2000 (Invitrogen) for 48 hours. Next, the luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega), and pRL-TK was used as an internal control. The experiments were performed in triplicate wells of a 96-well plate and repeated at least 3 times. In determining the effect of Cy-3-G or PCA, MPMs, and THP-1 macrophages preloaded with AcLDL (25 μg/mL) for 24 hours were cotransfected with 50 ng of the corresponding pGL3-WT and pRL-TK in the presence or absence of Cy-3-G or PCA (1 μmol/L) for 24 hours. The luciferase activity was then determined as described above.
Construction of Short-Hairpin RNA Plasmids
The short-hairpin RNA (shRNA) sequences for murine ABCA1 and ABCG1 were designed using Invitrogen's BLOCK-iT RNAi Designer. Negative control shRNA sequences for LacZ were provided by Invitrogen. cDNA oligonucleotides were annealed and cloned into pENTR/U6 (Invitrogen). The expression constructs were then generated by an LR recombination reaction between the pENTR/U6 entry construct and the pLenti6/BLOCK-iT-DEST expression construct (Invitrogen) according to the manufacturer's instructions. The final constructs were confirmed by DNA sequencing. The murine ABCA1 and ABCG1 RNAi sequences were 5′-TCCCTGGGTGTCAGTAATTCT-3′ and 5′-GGAAGTCCACACTCATGAATA-3′, respectively.
Lentiviral Vector Transduction
Lentiviral stocks were produced by cotransfecting the pLenti6/ BLOCK-iT-DEST constructs expressing shRNA targeting ABCA1 and ABCG1 or LacZ with ViraPower Packaging Mix (Invitrogen) into the 293FT Producer Cell Line (Invitrogen). These lentiviral stocks were then used to transduce J774 cells. Stably transduced cell lines were selected in DMEM supplemented with 10% FBS and 5 μg/mL blasticidin. ABCA1 or ABCG1 mRNA and protein levels in each cell line were determined by qRT-PCR or Western blotting, respectively.
Mouse Studies
Male ApoE −/− mice were weaned at 4 weeks of age and fed with an AIN-93G diet for another 26 weeks, at which point the mice were either euthanized (baseline, n=12) or subjected to the following experiments.
Experiment 1
The ApoE −/− mice fed with the AIN-93G diet in the absence and presence of an antibiotic cocktail (0.5 g/L vancomycin, 1 g/L neomycin sulfate, 1 g/L metronidazole, 1 g/L ampicillin) were orally gavaged with Cy-3-G (50 mg/kg body weight BW), PCA (5 mg/kg BW), or Cy-3-G (50 mg/kg BW) plus PCA (5 mg/kg BW) once daily for 14 days. On day 10, half of the mice (n=24) in each group were intraperitoneally injected with thioglycollate to elicit peritoneal macrophages. The remaining mice were individually housed in metabolic cages during the last 48 hours, and the efficiency of macrophage RCT in vivo was then quantified (described below).
Experiment 2
The ApoE −/− mice fed with the AIN-93G diet off and on an antibiotic cocktail were orally gavaged with Cy-3-G (50 mg/kg BW), PCA (5 mg/kg BW), or Cy-3-G (50 mg/kg BW) plus PCA (5 mg/kg BW) once daily for 4 weeks. At the end of the experimental period, overnight-fasted mice were anesthetized with isoflurane and exsanguinated by cardiac puncture. The MPMs, hearts, and thoracic and abdominal aortas were then collected for further analysis.
In Vivo Macrophage RCT Assay
RCT studies were performed as previously described. 26 Briefly, 3 H-cholesterol-labeled and AcLDL-loaded macrophages were resuspended in RPMI 1640 medium followed by intraperitoneal injection into the ApoE-deficient mice. 
Other Laboratory Procedures
Methods for the quantification of cellular protein expression by Western blotting, 27 plasma lipoprotein preparation and cellular lipid content, 7 plasma lipids and apolipoprotein A-I (ApoA-I) using commercial kits, cholesterol distribution in plasma lipoproteins separated by fast protein liquid chromatography (FPLC) gel filtration, 25 atherosclerosis at the aortic sinus, 14 and aortic cholesterol content 7 are shown in the Online Data Supplement.
Statistical Analysis
Results are presented as mean±SEM. The data were analyzed by 2-way repeated-measures ANOVA coupled with the post hoc Bonferroni-corrected t test, 1-way ANOVA coupled with the StudentNewman-Keuls multiple comparison test, or full factorial ANOVA (univariate general linear model) coupled with the independent Student t test where appropriate with the use of SPSS for Windows software (version 13.0; SPSS Inc, Chicago, IL). Statistical significance was accepted for P<0.05.
Results
PCA Is a Gut Microbiota Metabolite of Cy-3-G
ApoE
−/− mice were orally gavaged with Cy-3-G at 5 or 50 mg/kg BW that can be achieved in the human diet.
8 Cy-3-G feeding at 50 mg/kg BW resulted in a plasma Cmax of Cy-3-G and its metabolite PCA at 295 nmol/L or 979 nmol/L ( Figure 1A ), respectively. To determine the role of gut September 28, 2012 microbiota in the conversion of Cy-3-G to PCA, we applied 2 strategies. First, ApoE −/− mice were treated with antibiotics to eliminate the gut microbiota, resulting in the lack of detection of PCA in the plasma ( Figure 1B ). When the antibioticstreated mice were recolonized with normal gut microbiota, plasma PCA reappeared ( Figure 1C ). Second, germ-free mice orally fed Cy-3-G (50 mg/kg BW) did not produce PCA (Online Figure IA) , whereas these mice colonized with normal gut microbiota generated PCA after Cy-3-G oral administration (Online Figure IB) . Collectively, these data demonstrated that PCA is a gut microbiota metabolite of Cy-3-G.
PCA But Not Cy-3-G at Physiologically Reachable Concentrations Promotes Cholesterol Efflux From Macrophages In Vitro
We demonstrated previously that Cy-3-G at supraphysiological concentrations (10-100 μmol/L) promotes cholesterol efflux from macrophages to ApoA-I. 7 We showed that Cy-3-G at physiologically reachable concentrations (0.25-1 μmol/L) had no effect on cholesterol efflux from AcLDLloaded MPMs or THP-1 macrophages to ApoA-I or HDL (Figure 2A and 2B). However, PCA at physiologically reachable concentrations (0.25-1 μmol/L) greatly increased cholesterol efflux from the 2 AcLDL-loaded macrophages (Figure 2A and 2B). Additionally, there was no additive effect on cholesterol efflux from either AcLDL-loaded MPMs or THP-1 macrophages with the combination of PCA (1 μmol/L) and its precursor Cy-3-G (1 μmol/L) (data not shown). Because Cy-3-G at the concentration lower than 1 μmol/L could not affect macrophage cholesterol efflux, it was used as the negative control for further PCA studies unless otherwise indicated.
PCA at Physiologically Reachable Concentrations Induces ABCA1 and ABCG1 Expression Via Downregulating miR-10b Expression in Macrophages
ABCA1 is known to mediate the cholesterol efflux from macrophages to ApoA-I, whereas ABCG1 and scavenger receptor class B type I (SR-BI) facilitate the cholesterol efflux from macrophages to HDL. 20 We found by qRT-PCR and Western blotting that PCA but not Cy-3-G increased ABCA1 and ABCG1 but not SR-BI expression in AcLDLloaded MPMs ( Figure 2C and 2D) and THP-1 macrophages ( Figure 2E and 2F). To investigate how PCA stimulates ABCA1 and ABCG1 expression, we applied 2 strategies. As ABCA1 and ABCG1 are transcriptionally regulated by liver X receptor alpha (LXRα), 28 we have first assessed the effect of PCA on the ABCA1 or ABCG1 promoter activities using human ABCA1 or ABCG1 promoter luciferase fusion gene constructs. Both PCA and Cy-3-G (0.25-1 μmol/L) showed no appreciable effect on human ABCA1 or ABCG1 promoter activities in AcLDL-loaded MPMs or THP-1 macrophages (Online Figure II A Furthermore, PCA or Cy-3-G had no effect on LXRα activation by assessing liver X receptor element (LXRE)-mediated luciferase activity (Online Figure III E and F). Next, ActD was used to assess the mRNA stability of ABCA1 and ABCG1. We found that PCA but not Cy-3-G (1 μmol/L) significantly prolonged the half-lives of ABCA1 and ABCG1 mRNA in AcLDL-loaded MPMs and THP-1 macrophages ( Figure 2G and 2H). We have also investigated whether PCA modulates 3′-UTRs, a mechanism that destabilizes mRNA. As shown in Figure 2I and 2J, PCA but not Cy-3-G (1 μmol/L) restored the attenuated luciferase reporter activities induced by the presence of mouse and human ABCA1 or ABCG1 3′-UTR. We hence suggest that PCA posttranscriptionally regulates ABCA1 and ABCG1 mRNA expression, at least in part, through enhancing the stability of those mRNAs mediated by their 3′-UTR sequences.
miRNA plays critical roles in mRNA stability via interacting with 3′-UTRs of their target gene. 29 Several flavonoids were shown to affect miRNA expression. 30 We then performed unbiased miRNA microarray analysis with the chip containing 1055 miRNA probes. Online Table II shows that the expression of four miRNAs (miR-10b, 300, 370, and 493) was at least 2-fold different in the PCA-treated MPMs compared with vehicle-treated cells. qRT-PCR further confirmed that PCA but not Cy-3-G (1 μmol/L) induced these 4 miRNAs changes in AcLDL-loaded MPMs ( Figure 3A ) and J774 murine macrophages (Online Figure IV) . In AcLDL-loaded THP-1 macrophages, except for miR-493, the other 3 miRNAs were also shown to be regulated by PCA ( Figure 3B ). Using several miRNA target prediction databases, 31 we identified putative binding sites for miR-10b in the 3′-UTR of mouse and human ABCA1 and ABCG1 genes (show in the bottom panels of Figure 3E and 3F).
To evaluate the effects of miR-10b on the 3′-UTR of mouse and human ABCA1 and ABCG1, we used luciferase reporter constructs. We found that miR-10b dose-dependently repressed ABCA1 or ABCG1 3′-UTR activities of either mouse or human origins ( Figure 3C and 3D) . To ensure the specificity of these interactions, mutants of ABCA1 and ABCG1 3′-UTR of either mouse or human origins that contained a 4-nt change in the seed region of the target sequence were constructed ( Figure 3E and 3F, bottom panels). The mutation of the miR-10b target sites relieved miR-10b repression of mouse and human ABCA1 and ABCG1 3′-UTR activities ( Figure 3E and 3F, top panels), consistent with a direct interaction of miR10b with these sites. Furthermore, miR-10b strongly decreased both ABCA1 and ABCG1 mRNA and protein expression in AcLDL-loaded MPMs ( Figure 3G and 3H) and THP-1 macrophages ( Figure 3I and 3J), whereas antagonism of endogenous miR-10b increased their expression in both cells ( Figure 3K  through 3N ). Together, these observations suggest that ABCA1 and ABCG1 are functional targets of miR-10b.
Next, we tested whether miR-10b affects the ability of macrophages to efflux free cholesterol. As shown in Figure 4A and 4B, miR-10b attenuated cholesterol efflux from both AcLDLloaded MPMs and THP-1 macrophages to ApoA-I and HDL, whereas antagonism of endogenous miR-10b increased the cholesterol efflux ( Figure 4C and 4D) .
To further explore the role of miR-10b in PCA-induced ABCA1 and ABCG1 expression in macrophages and its induced cholesterol efflux function, we used gain-of-function (overexpressed miR-10b) and loss-of-function (down-expressed miR-10b) assays in AcLDL-loaded MPMs. The results of the gain-of-function experiment revealed that PCA treatment reversed the inhibitory effects of miR-10b on the expression of ABCA1 and ABCG1 at both protein and mRNA levels ( Figure 5A and 5B), as well as cholesterol efflux to ApoA-I and HDL ( Figure 5C ), whereas PCA-induced functions were not observed in AcLDL-loaded MPMs transfected with antienmiR-10b (Figure, 5A, 5D , and 5E). Additionally, Cy-3-G did not show any significant effect in these testing systems as PCA did ( Figure 5A through 5E ). Because PCA also markedly reduced miR-300 and increased the expression of miR-370 and miR-493 ( Figure 3A) , we further evaluated the potential effects of these miRNAs on cholesterol efflux from AcLDL-loaded MPMs. Antagonism of endogenous miR-300 (Online Figure VA) or overexpression of miR-370 or 493 (Online Figure VB and C) had no effect on cholesterol efflux from the cells. Collectively, the observations imply that the stimulatory effects of PCA on cholesterol efflux from AcLDL-loaded MPMs via upregulating ABCA1 and ABCG1 expression involve the downregulation of miR-10b.
PCA Is Responsible for the Stimulatory Efficacy of Cy-3-G on Macrophage RCT In Vivo
To test whether the in vitro findings on cholesterol efflux from macrophages by PCA could be extended into the in vivo circumstances, 30-week-old male ApoE −/− mice were orally gavaged once daily with PCA (5 mg/kg BW) for 14 days. PCA feeding resulted in approximately 0.8 μmol/L PCA in the circulatory system (Online Figure VI) , which is effective in driving cholesterol efflux from macrophages in vitro (Figure 2A and 2B ). MPMs isolated from mice treated with PCA for 14 days had lower levels of cellular miR-10b ( Figure  6A ), associated with increased ABCA1 and ABCG1 expression at both mRNA and protein levels ( Figure 6B through 6D), as well as enhanced cholesterol efflux ability to ApoA-I or HDL ( Figure 6E and 6F ). Because feeding with Cy-3-G (50 mg/kg BW) produced similar levels of plasma PCA (Figure 1 and Online Figure VI) , it is assumed that Cy-3-G at a higher dose may have an analogous effect with PCA. As result, orally feeding Cy-3-G (50 mg/kg BW) in 30-weekold male ApoE −/− mice for 14 days improved the cholesterol efflux, similar to the effect by a lower-dose PCA feeding ( Figure 6A through 6F) .
To further verify that Cy-3-G-induced beneficial effects ( Figure 6A through 6F) depend on its gut microbiota metabolite PCA, mice that received Cy-3-G or PCA were concomitantly administered antibiotics. Notably, antibiotics administration completely abolished the Cy-3-Geninduced effects, including the repression of miR-10b, the activation of ABCA1 and ABCG1, as well as the stimulation of cholesterol efflux in isolated MPMs ( Figure 6A through 6F) , whereas antibiotics had no effect on PCA-induced changes ( Figure 6A through 6F). To further verify whether PCA is required for the effects induced by its parent Cy-3-G, we examined the impact of Cy-3-G (50 mg/kg BW) plus PCA (5 mg/kg BW) with or without antibiotics treatment. Evidently, Cy-3-G plus PCA reversed the inhibitory effect of antibiotics on Cy-3-Geninduced effects ( Figure 6A through 6F) . Moreover, there was an additive effect between Cy-3-G and PCA without antibiotics treatment ( Figure 6A through 6F) .
To determine whether the changes of ABCA1 and ABCG1 expression are regulated by miR-10b, we examined a time course of their expression in isolated MPMs related to the pharmacokinetics of PCA in ApoE-deficient mice. The mice were treated orally with PCA (5 mg/kg BW) for 0 to 16 hours. The variation tendency of PCA concentrations in plasma, miR-10b, and ABCA1/ABCG1 mRNA expression in isolated MPMs were showed in Online Figure VII . Plasma PCA concentration reached the peak at 0.5 hours, whereas the level of macrophage miR-10b began to decrease at 1 hour, reached the lowest at 4 hours, then maintained lower level till 16 hours. ABCA1 and ABCG1 mRNA expression started to increase at 2 hours, reached the highest at 8 hours, then remained at higher level until 16 hours. The lag response of ABCA1 and ABCG1 to miR-10b suggests that PCA may first reduce miR-10b levels and then in turn induce ABCA1 and ABCG1 expression.
Consistent with the results from the ex vivo studies, a 14-day intervention with Cy-3-G (50 mg/kg BW) or PCA (5 mg/kg BW) significantly increased the cholesterol transport from macrophages to feces in the ApoE −/− mice ( Figure 6G ). Moreover, antibiotics treatment blocked the positive effect of Cy-3-G but not PCA on macrophage RCT ( Figure 6G ), whereas the inhibitory effect of antibiotics on Cy-3-Geninduced macrophage RCT was reversed by cotreatment with PCA ( Figure 6G ). In contrast, both Cy-3-G and PCA had no significant effect on cholesterol tracer recovery in the liver at 48 hours ( Figure 6H ) or in plasma at 6, 24, and 48 hours ( Figure 6I ). Taken together, these data suggest that the Cy-3-Genmediated macrophage RCT is at least mainly, if not completely, dependent on its gut microbiota metabolite PCA, involving the repression of miR-10b and the activation of ABCA1 and ABCG1-cholesterol efflux pathway in macrophages.
Macrophage ABCA1 and ABCG1 Are Partially Responsible for the Stimulatory Effect of PCA on Macrophage RCT In Vivo
Because PCA markedly increased 3 H-tracer recovery in feces but not in plasma and liver, we then performed a proof-of-principle study to investigate how importantly PCA-induced macrophage cholesterol efflux does contribute to PCA-enhanced RCT in ApoE-deficient mice. We first constructed lentiviral vectors that drive the expression of a shRNA targeting murine ABCA1 or ABCG1 and used both of them to transduce J774 macrophages to obtain cell lines in which the expression of both ABCA1 and ABCG1 has been knocked down (J774-DKD). J774 macrophages transduced with a lentiviral vector encoding LacZ shRNA (J774-Con) and nontransfected cells served as the control cells. ABCA1 and ABCG1 mRNA (Online Figure VIIIA and B) as well as their protein expression ( Figure 6J ) were significantly lower in J774-DKD macrophages than J774-Con cells in either the absence or presence of AcLDL. As expected, a substantial reduction in cholesterol efflux to ApoA-I or HDL from the AcLDL-loaded J774-DKD cells was observed compared with the AcLDLloaded J774-Con cells (Online Figure VIIIC and D) . Moreover, in agreement with a previous study, 20 ApoE-deficient mice injected with 3 H-cholesterol and AcLDL-loaded J774-DKD macrophages had a lower ability to transport cholesterol from macrophages to feces than the control mice injected with AcLDL-loaded J774-Con cells ( Figure 6K ). Thus, knockdown of ABCA1 and ABCG1 in J774-DKD cells effectively impaired macrophage cholesterol efflux in vitro and in vivo.
Next, we performed a 2×2 factorial design of RCT study with 2 factors (named A and B). Factor A is 
PCA Masters the Regressive Potential of Its Precursor Cy-3-G on Established Atherosclerotic Lesions
Macrophage RCT plays a key role in the formation and/or regression of cholesterol-loaded macrophage foam cells. Figure  7A and 7B) , whereas the inhibitory effect of antibiotics on the Cy-3-Geninduced regressive effect was restored by cotreatment with PCA ( Figure 7A and 7B) . On day 12, 3H-cholesterolenlabeled and AcLDL-loaded MPMs (3.6×106 cells at 3.9×106 cpm per mouse) were intraperitoneally injected into the mice (n=12 per group). After cell injection, blood at 6, 24, and 48 hours, liver at 48 hours (after the animals were euthanized), and feces within the 48-hour experimental period were collected for the analysis of macrophage RCT. 3H-cholesterol recovery in the feces (G), liver (H), and plasma (I). Results in G, H, and I are mean±SEM, n=12. *P<0.05 vs. control Abx (−); #P<0.05. J, Reduction in ABCA1 and ABCG1 expression on the protein level was determined in J774 macrophages stably transfected with vectors encoding for shRNA against mouse ABCA1 (shABCA1) and ABCG1 (shABCG1) that were loaded with or without AcLDL (25 μg/mL) for 24 hours. As control, cells transfected with vector encoding for shRNA against LacZ (J774-Con) or nontransfected cells (NT) were used. J, Representative image of 3 independent experiments. K, Double knockdown of ABCA1 and ABCG1 in J774 macrophages (J774-DKD) impairs cholesterol efflux in vivo. Thirty-week-old male ApoE−/− mice were intraperitoneally injected with 3H-cholesterolenlabeled and AcLDL-loaded J774-DKD macrophages (3.8×106 cells at 4.3×106 cpm per mouse) or J774-Con cells (4.3×106 cells at 5.2×106 cpm per mouse). After cell injection, feces within 48 hours were obtained and 3H-tracer levels were measured. Results are mean±SEM, n=8. #P<0.05. L and M, Thirty-week-old male ApoE−/− mice were orally gavaged with PCA (5 mg/kg BW) (L), Cy-3-G (50 mg/kg BW) (M), or vehicle once daily for 14 days. On day 12, 3H-cholesterolenlabeled and AcLDL-loaded J774-DKD (4.7×106 cells at 5.2×106 cpm per mouse) and J774-Con (4.5×106 cells at 4.7×106 cpm per mouse) were intraperitoneally injected into the mice. Feces within 48 hours were obtained and 3H-tracer levels were measured. Results are mean±SEM, n=12. #P<0.05.
Finally, we determined whether the changes in RCT and macrophage foam cells induced by Cy-3-G, or PCA, or Cy-3-G plus PCA are associated with atherosclerosis regression in ApoE −/− mice. As shown in Figure 7C and 7D, both the atherosclerotic lesion area in the aortic sinus and the cholesterol content in the whole aorta, as the indexes for the severity of atherosclerosis, were lower in Cy-3-Gentreated, PCA-treated, or Cy-3-G plus PCAentreated mice. However, antibiotics abolished the regressive effect of Cy-3-G but not PCA on established atherosclerosis (Figure 7C and 7D) . Moreover, cotreatment with PCA reversed the suppressive effect of antibiotics on the Cy-3-Geninduced regressive effect ( Figure  7C and 7D) . Collectively, these data implied that the effect of Cy-3-G on the regression of atherosclerosis depends on its gut microbiota metabolite PCA.
Important drivers of atherosclerotic lesion regression are plasma lipids and ApoA-I. The Table shows that Cy-3-G but not PCA reduced plasma total cholesterol (TC) and total triglyceride (TG) and increased HDL-C and ApoA-I levels. Evidently, antibiotics selectively abrogated the incremental effect of Cy-3-G on the plasma HDL-C and ApoA-I levels (Table) . FPLC analysis of pooled plasma samples further showed that Cy-3-G especially decreased cholesterol contents in the fraction of VLDL (Online Figure IX) . These data suggest that Cy-3-G alone is sufficient to decrease plasma TC and TG content, whereas PCA is a perquisite for its parent Cy-3-G to elevate HDL-C and ApoA-I levels. 
Discussion
The current study demonstrated that pure anthocyanin Cy-3-G accelerates macrophage RCT and promotes the regression of established atherosclerosis in the ApoE −/− mouse model. Utilizing antibiotics-treated and germ-free mice, we revealed that Cy-3-G is metabolized into PCA via the gut microbiota. Of note, we observed that these beneficial effects of Cy-3-G are at least mainly, if not completely, dependent on its gut microbiota metabolite PCA. We showed for the first time that miR-10b negatively regulates cholesterol efflux from murineand human-derived macrophages by repressing the expression of ABCA1 and ABCG1, whereas PCA reduces miR-10b levels, leading to enhanced cholesterol efflux from macrophages. Taken together, our data provided the unequivocal evidence that gut microbiota modulates the potency of Cy-3-G in promoting macrophage RCT and regressing atherosclerosis in vivo. At the same time, this finding also provided new insight that the gut microbiota is an attractive therapeutic target for regressing established atherosclerosis. Because anthocyanins are poorly absorbed in the gut, it has been doubtful that relatively low concentrations of intact anthocyanins in vivo could account for these notable beneficial effects. Recently, it has been reported that substantial amounts of unabsorbed anthocyanin undergo extensive metabolic transformation in the colon via the gut microbiota, producing a wide range of aromatic and phenolic compounds. 11 Several in vivo studies showed that one of these compounds, PCA, can be detected in the systemic circulation of rats and humans after the consumption of the parent compounds. 12, 33 In addition to the gut bacterial transformation, several studies showed that anthocyanin could be spontaneously degraded into to PCA in vitro under physiological conditions at neutral pH such as intestinal content and cell culture mediums. 17 In the current study, we provided the evidence that PCA is a gut microbiota metabolite of Cy-3-G. PCA could not be detected in plasma in germ-free Kunming mice fed with Cy-3-G, or in Cy-3-Genfed ApoE −/− mice treated with antibiotics. These findings suggest that spontaneous degradation of anthocyanin into PCA has limited physiological relevance during Cy-3-G intervention. In addition to anthocyanin, many other flavonoids are also poorly absorbed and undergo extensive gut microbiota metabolism. [34] [35] [36] It is reasonable to expand our study into other flavonoids and to hypothesize that other gut microbiota metabolites of the parent flavonoids may also play important biological roles.
We found that PCA but not Cy-3-G selectively induces ABCA1 and ABCG1 expression in an LXRα-independent manner. Instead, PCA regulates the cholesterol efflux from murine-and human-derived macrophages by posttranscriptional regulation of the 3′-UTR of ABCA1 or ABCG1 transcript through downregulating miR-10b level. We hence conclude that in addition to miR-33 22 and miR-758, 23 miR10b is the third miRNA that is involved in functionally regulating macrophage cholesterol efflux. It is worth noting that a recent study shows that miR-10b level is significantly increased in the atherosclerotic plaque tissue of human subjects, 37 suggesting that miR-10b is a novel therapeutic target for preventing atherosclerotic development. The observation that antagonism of miR-33 in LDL receptorendeficient mice markedly promotes macrophage RCT partially via increasing macrophage ABCA1 and ABCG1 expression 38 prompted us to hypothesize that miR-10b may function in a similar way as miR-33. Supporting our hypothesis, we found that PCA could promote macrophage RCT in mice and also alter expression of miR-10b and ABCA1/ABCG1 in isolated MPMs. Because the cause-effect relationship between miR-10b and ABCA1/ ABCG1 mediated by PCA is ambiguous, we performed a time-course experiment. The results revealed sequential changes: first, appearance of plasma PCA, then macrophage miR-10b level decreased; last, ABCA1/ABCG1 expression increased. These findings strongly imply that PCA induces macrophage ABCA1 and ABCG1 expression in vivo, at least in part, through downregulation of miR-10b. Interestingly, plasma PCA is rapidly eliminated from circulation, but its downstream effects of miR-10b and ABCA1/ABCG1 last for a much longer duration. This phenomenon may be explained by longer stability of miR-10b, which is consistent with the concept that the half-lives of miRNAs usually ranged from 28 to 220 hours. 39 Furthermore, we demonstrated that the potency of PCA in accelerating in vivo macrophage RCT is reduced by 55.4% when macrophage ABCA1 and ABCG1 were knocked down. Because ABCA1 and ABCG1 in J774-DKD macrophages were not completely knocked down in our cell models, we speculate that the contribution of macrophage cholesterol efflux mediated by ABCA1 and ABCG1 to the PCA-induced macrophage RCT may have been underestimated.
How PCA affects miR-10b expression in macrophages is currently unknown. Several groups have independently revealed that expression of miR-10b can be induced by the transcription factor Twist that directly binds to the putative promoter of miR-10b. 40 Twist is positively regulated by CD44, 41 which could be induced by tumor necrosis factor-α (TNF-α). 42 Given that the macrophages express CD44 and Twist, 42, 43 and PCA can inhibit TNF-α production in lipopolysaccharide-induced macrophages, 44 we wonder whether PCA decreases miR-10b expression through the inhibition of the CD44-activated Twist pathway via decreasing TNF-α production. This is worth further examination. Although numerous flavonoid-rich foods, extracts rich in flavonoids, and individual flavonoids are able to inhibit the early stages of atherosclerosis in animal models, 36 no specific flavonoid has been shown to regress the advanced stages of atherosclerosis. We have found previously that anthocyanin extract from black rice (rich in Cy-3-G) significantly attenuated the progression of advanced plaque lesions in the ApoE −/− mouse model. 3 The current work revealed for the first time that an individual purified anthocyanin Cy-3-G promotes the regression of advanced plaque lesions. Mechanistically, we proposed that this effect is probably achieved with the aid of its gut microbiota metabolite PCA. It has been shown that Cy-3-G inhibits the formation of early atherosclerosis through several potential mechanisms: antioxidation, 6 antimonocyte infiltration, 13 and elevating plasma HDL-C levels. 3 However, it is very unlikely that those effects largely contribute to the regressive effect of Cy-3-G on established atherosclerosis. First, antioxidants therapies, such as vitamin E, vitamin C, or β-carotene supplementation, have no regressive effect on already established atherosclerosis in numerous preclinical and clinical studies. 45 Second, it is generally accepted that the antimonocyte infiltration by downregulation of CC chemokine receptor 2 expression could not inhibit the progression of established atherosclerosis in the same ApoE −/− mouse model. 46 Finally, in contrast to the recent finding that HDL could promote atherosclerosis regression partially by its antiinflammatory property, 47 the elevated plasma HDL-C levels by Cy-3-G treatment did not cause a more favorable effect on atherosclerosis regression than PCA treatment in present study. This paradoxical phenomenon indicated that HDL in the Cy-3-Gentreated mice may not be functional in regressing atherosclerotic lesion. Supporting this speculation, a previous study has demonstrated that HDL derived from ApoE −/− mice is proinflammatory. 48 Thus, the present findings may further support the concept that functional properties of HDL rather than mere HDL concentration faithfully reflect the atheroprotective potency of HDL. 19 A single miRNA may target more than 100 mRNAs, whereas a single mRNA could be regulated by different miRNAs. In addition to the promotion of macrophage RCT through posttranscriptional regulation of ABCA1 and ABCG1, PCA may promote lesion regression through other targets of miR-10b, such as Kruppel-like factor 4 (KLF-4) 49 and homeobox D10 (HOXD10). 50 KLF-4 was shown to play a critical role in regulating macrophage polarization from a proinflammatory to an anti-inflammatory functional phenotype. 51 HOXD10 represses several genes involved in cell migration and extracellular matrix remodeling. 50 If miR-10b functionally targets KLF4 and HOXD10 in macrophages or vascular cells such as endothelial cells, PCA may reduce atherosclerosis partially via inhibiting the miR-10b-inflammatory pathway and improving extracellular matrix remodeling in the atherosclerotic plaques besides its promotion of RCT.
The gut microbiota forms an enormous and diverse ecosystem known to function in nutrient absorption, vitamin production, gut epithelial cell health, and innate immunity. 52 The gut microbiota has also been implicated in the development of several metabolic phenotypes, such as obesity, insulin resistance, and atherosclerosis. [53] [54] [55] [56] Alterations in the composition of the intestinal ecosystem can influence the development of chronic disease by affecting the dominant bacteria and the production and absorption of endogenous endotoxins, which can trigger inflammation in obesity and type 2 diabetes. 57, 58 In addition, nutritional substances undergo metabolism by the gut microbiota, and their metabolites subsequently induce various functions. 59 A recent study revealed the direct link between the gut microbiota, dietary phosphatidylcholine, and cardiovascular disease risk. 60 Furthermore, it was proposed that a gut microbiota metabolite of isoflavone, equol, is a critical factor contributing to the beneficial effects of its parent, isoflavone. 61 The present study revealed the importance of PCA as a gut microbiota metabolite of the parent anthocyanin, being substantially responsible for the antiatherosclerotic effects of dietary anthocyanin. These observations collectively indicate that intestinal microbiota plays a critical role in the development of chronic disease. Additionally, the intestinal microbiota ecosystem is a potential target for the prevention and treatment of chronic diseases.
Cholesterol effluxed from macrophages is carried by plasma HDL in the removal of cellular cholesterol excess. The plasma concentration of effluxed cholesterol from macrophages is affected by many components of RCT, including the clearance rate by the liver. 62 A few recent studies evidenced that HDL also deliver cholesterol to intestinal tissue and that the cholesterol is then directly transported into intestinal lumen without metabolism in the liver. 63 Therefore, the plasma 3 H-tracer levels could not faithfully reflect the cholesterol efflux from macrophage. The present results showed that plasma and hepatic 3 H-tracer levels did not differ from the control group after PCA administration. It is possible that PCA promotes cholesterol transportation of HDL from intestinal tissue into gut lumen or reduces intestinal cholesterol and bile acid reabsorption, thus partially contributing to PCA-induced macrophage RCT. Nevertheless, the effect of PCA on cholesterol transport in intestinal tissue requires further investigation.
In summary, we present the following model for the role of Cy-3-G in promoting RCT and regressing established atherosclerosis in the ApoE −/− mouse model ( Figure 7E ): dietary Cy-3-G is intensively metabolized into PCA by the gut microbiota, and the latter induces ABCA1 and ABCG1 expression in macrophages by decreasing the expression of miR-10b, which contributes to the accelerated macrophage RCT. As a consequence, enhanced macrophage RCT can, at least in part, result in the regression of established atherosclerosis. Importantly, the observations made in this study allow us to propose that gut microbiota is a potential and promising target for the promotion of macrophage RCT and hence atherosclerosis regression in humans.
